Next, CD44+ PD-1+ Tim3− stem-P14s were sorted from the TdLNs and transferred into B16F10GP tumor-bearing mice, followed by treatment with RT with or without anti-PD-L1 3 days later (Figure 5E, S5A). This evidence concerns the gene CD44 and neoplasm.